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Aim: The SONAR trial uses an enrichment design based on the individual response to the selective
endothelin receptor antagonist atrasentan on efficacy (the degree of the individual response in the
urinary albumin-to-creatinine ratio [UACR]) and safety/tolerability (signs of sodium retention and
acute increases in serum creatinine) to assess the effects of this agent on major renal outcomes.
The patient population and enrichment results are described here.
Methods: Patients with type 2 diabetes with an estimated glomerular filtration rate (eGFR)
within 25 to 75 mL/min/1.73 m2 and UACR between 300 and 5000 mg/g were enrolled. After
a run-in period, eligible patients received 0.75 mg/d of atrasentan for 6 weeks. A total of 2648
responder patients in whom UACR decreased by ≥30% compared to baseline were enrolled, as
were 1020 non-responders with a UACR decrease of <30%. Patients who experienced a weight
gain of >3 kg and in whom brain natriuretic peptide exceeded ≥300 pg/mL, or who experienced
an increase in serum creatinine >20% (0.5 mg/dL), were not randomized.
Results: Baseline characteristics were similar for atrasentan responders and non-responders.
Upon entry to the study, median UACR was 802 mg/g in responders and 920 mg/g in non-
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responders. After 6 weeks of treatment with atrasentan, the UACR change in responders was
−48.8% (95% CI, −49.8% to −47.9%) and in non-responders was −1.2% (95% CI, −6.4% to
3.9%). Changes in other renal risk markers were similar between responders and non-responders
except for a marginally greater reduction in systolic blood pressure and eGFR in responders.
Conclusions: The enrichment period has successfully identified a population with a profound
UACR reduction without clinical signs of sodium retention in whom a large atrasentan effect on
clinically important renal outcomes is possible. The SONAR trial aims to establish whether atra-
sentan confers renal protection.
KEYWORDS
atrasentan, diabetic kidney disease, endothelin receptor antagonist, precision medicine,
randomized controlled clinical trial
1 | INTRODUCTION
It has become increasingly apparent that the effects of treatment can
vary among subgroups of patients with diabetic kidney disease.1,2
Biomarker-driven enrichment clinical trials are aimed at identifying
individual patients who are more likely to benefit from new therapies
and less likely to experience side effects; consequently, they have the
potential to increase the success rate of confirmatory clinical trials
and promote personalized medicine.
As described in the accompanying design manuscript, the Study
Of diabetic Nephropathy with AtRasentan (SONAR trial) is a clinical
trial that aims to test the renoprotective effects of the selective
endothelin receptor antagonist atrasentan in patients at high risk of
progressing to end-stage renal disease.3–5 The trial design includes a
biomarker-based enrichment period to attempt to identify individuals
most likely to benefit from the study drug prior to randomization. In
the case of atrasentan, this means identifying patients based on signif-
icant clinical albuminuria reduction with minimal sodium retention. To
achieve this, all those patients who fulfilled the entry criteria of the
trial entered an enrichment period and received 0.75 mg/d of atrasen-
tan for 6 weeks. Patients with a significant albuminuria response to
atrasentan (≥30% reduction in urinary albumin-to-creatinine ratio
[UACR]) without significant sodium and fluid retention proceeded to
randomization, and they comprised the primary population for asses-
sing the efficacy and safety of atrasentan. Approximately a thousand
non-responders (UACR reduction of <30% from baseline) were also
randomized to double-blind treatment in a parallel study stratum in
order to determine if atrasentan delays progression of renal function
decline in patients with a modest albuminuria reduction.3
This article describes the baseline characteristics of the atrasen-
tan responder and non-responder populations and the results of the
enrichment period.
2 | METHODS
2.1 | Study population
The detailed design, rationale, and study endpoints of the SONAR trial
are described in the accompanying publication.3 Briefly, the trial is
being conducted at 795 clinical sites in 41 countries. All the patients
are aged 18 to 85 years old with type 2 diabetes (T2D) and an esti-
mated glomerular filtration rate (eGFR) of 25 to 75 mL/min/1.73 m2,
a UACR ≥300 mg/g and creatinine <5000 mg/g, and a B-type natri-
uretic peptide (BNP) ≤ 200 pg/mL. The main exclusion criteria were
type 1 diabetes, a history of severe edema, pulmonary hypertension,
or heart failure. In order to enter the enrichment period, patients had
to be on a stable and maximum tolerated labelled dose of an
angiotensin-converting enzyme inhibitor or an angiotensin receptor
blocker and a diuretic, unless medically contraindicated. The study
protocol is registered with ClinicalTrials.gov (www.clinicaltrials.gov
[NCT01858532]). The study protocol was approved by an indepen-
dent ethics committee and local and central review boards. All partici-
pants signed a consent form before the start of any study-specific
procedure.
2.2 | Enrichment period
Patients who fulfilled the entry criteria and then completed a run-in
period during which renin-angiotensin aldosterone system inhibitors
and/or diuretic treatment was optimized, received 6 weeks of open
label treatment with atrasentan. Baseline UACR for the enrichment
period was defined as the geometric mean of all available UACR
values obtained at the last visit of the run-in period and the first
enrichment visit before atrasentan administration. A minimum of
3 out of 6 scheduled samples was required to proceed. Final UACR
for the enrichment period was defined as the geometric mean of all
available UACR values obtained at weeks 5 and 6 of the enrichment
visits. A minimum of 3 out of 6 scheduled samples was required to
proceed. A chemistry panel including serum creatinine, higher baseline
glycated haemoglobin (HbA1c), potassium, albumin, and hematocrit,
was measured at the start and end of enrichment. Blood pressure,
body weight and peripheral edema assessment were recorded at the
start of enrichment and then after 1, 2, 4 and 6 weeks.
Patients who experienced weight gain of >3 kg during enrich-
ment, and in whom the absolute serum BNP exceeded ≥300 pg/mL
(300 ng/L) at the last enrichment visit, were not eligible to proceed to
the double-blind treatment period. Also, patients in whom serum cre-
atinine increased by more than 20% and 0.5 mg/dL during enrichment
were not eligible to proceed to the double-blind treatment period.
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Patients with a ≥30% reduction in UACR from the beginning to the
end of the enrichment period were randomized into the responder
stratum, whereas those with a <30% reduction in UACR were ran-
domized into the non-responder stratum.3 Randomization was strati-
fied by geographic region, baseline UACR level (≤ or >1000 mg/g),
and the category of UACR reduction achieved during the enrichment
period. UACR reduction categories were defined as ≥60%, ≥45% to
<60%, and ≥30% to <45% for the responder population, and ≥15% to
<30%, ≥0% to <15%, and <0% for the non-responder population.
2.3 | Statistical analyses
In general, baseline characteristics with continuous data were
reported as mean and standard deviation (SD), characteristics with
skewed distribution were reported as median and interquartile range
[IQR], and categorical variables were reported as number and percent-
age. The absolute changes (end of enrichment – start of enrichment)
for all parameters during enrichment (except for UACR and BNP) were
summarized. For UACR and BNP, the absolute changes on a log scale
were calculated. A transformation was then applied to summarize the
per cent change from baseline. For all mean changes 95% confidence
intervals (CI) are provided. Analyses were performed using SAS ver-
sion 9.3 (SAS Institute, Cary, NC).
3 | RESULTS
3.1 | Baseline characteristics
Out of the 11 088 patients screened, 5107 entered enrichment. Of
these, 4703 patients completed enrichment, while 404 did not. A total
of 2648 patients were responders and were enrolled in the UACR
responder stratum, while 1889 were non-responders, and a selection
of 1020 of these patients were randomized into a separate non-
responder stratum. The baseline characteristics of the 2648 responders
and 1020 non-responders are shown in Table 1. Baseline characteris-
tics were numerically similar between responders and non-responders.
(The possible impact of small differences in baseline characteristics on
renal outcomes will be tested later upon completion of the SONAR
trial.) The median entry UACR level in responders was 802 mg/g (25th
to 75th percentile, 450-1466 mg/g). In non-responders it was
920 mg/g (25th to 75th percentile, 474-1858 mg/g). A renin-
angiotensin system inhibitor was used in 98% of patients, and more
than 80% used diuretic treatment (Table 1). A history of coronary
artery disease was recorded in approximately 11% of the population at
the start of enrichment.
3.2 | Responses in albuminuria and other
cardio-renal risk markers
A large difference in albuminuria response was observed between
atrasentan responders and non-responders. After 6 weeks of treat-
ment with atrasentan, median UACR was reduced in responders to
401 mg/g, representing a mean change from baseline of −48.8% (95%
CI, −49.8% to −47.9%). In non-responders the median UACR after
6 weeks of treatment with atrasentan was 867 mg/g, representing a
mean change from baseline of −1.2% (95% CI, −6.4% to 3.9%)
(Figure 1). Among the randomized responders (N = 2648), 591 partici-
pants (22.3%) were randomized in the ≥60% UACR reduction stratum;
968 (36.6%) in the ≥45% to <60% UACR reduction stratum; and 1089
(41.1%) in the ≥30% to <45% UACR reduction stratum. Among the
randomized non-responders (N = 1020), 479 participants (47.0%)
were in the ≥15% to <30% UACR reduction stratum; 286 (28.0%) in
the ≥0% to <15% UACR reduction stratum; and 255 (25.0%) in the
UACR >0% increase stratum.
The effects of atrasentan on all other measured cardio-renal risk
markers were similar for both responders and non-responders
(Figure 1), except for systolic blood pressure and eGFR, both of which
showed a larger reduction in the responder group. While the mean
change in BNP was approximately 30% in both responders and non-
responders, that change was attributed to outliers because median
changes were approximately 8% in both responders and non-
responders.
Upon entering the enrichment period, 42 patients in the
responder population and 9 patients in the non-responder population
used a sodium glucose co-transporter 2 (SGLT2) inhibitor. The effect
of atrasentan on UACR reduction was consistent and similar among
those participants who used and didn't use SGLT2 inhibitors, both in
the responder and non-responder populations (Table 2).
4 | DISCUSSION
SONAR is the first clinical trial in diabetic kidney disease that employs
a biomarker-based enrichment design to better identify patients who
may respond to and tolerate a new investigational drug. The comple-
tion of the enrichment phase of the SONAR trial illustrates the practi-
cal feasibility of this approach. The results show that the enrichment
period has differentiated the UACR response from the UACR non-
response population. Interestingly, the baseline characteristics were
similar for both populations, indicating that the UACR response to
atrasentan is unlikely to be predicted by any of the usual baseline
characteristics. Responses in systolic blood pressure and eGFR were
slightly larger in responders compared to non-responders, but
responses in other cardio-renal risk markers were similar between the
2 populations.
The baseline characteristics show that the SONAR trial enrolled a
population at high risk of progressive decline in kidney function. In
the responder population more than half of all patients had a UACR
>800 mg/g, and more than half had an eGFR <42 mL/min/1.73 m2.
The population was generally well treated with drugs aimed at
improving important cardiovascular and renal risk factors. Almost all
the patients received multiple treatments to control their blood pres-
sure, and yet mean blood pressure remained above the recommended
target, highlighting the difficulty in treating hypertension when kidney
function declines. By design, the use of diuretic treatment was recom-
mended in the protocol because endothelin receptor antagonists
(ERAs) can cause sodium and fluid retention. More than 80% of all
patients received such treatment, which is higher than in other trials
with similar patients.6,7 Insulin was used in more than 60% of all
patients, and statins in nearly 80%.
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TABLE 1 Baseline characteristics in the SONAR randomized responder (≥30% decline in UACR) and non-responder (<30% decline in UACR)
population; both groups exclude patients with clinical signs of sodium retention and acute increases in serum creatinine; data are presented as
mean (SD) unless otherwise noted
Variable
Atrasentan responders
N = 2648
Atrasentan non-responders
N = 1020
Age, years 64.8 (8.7) 63.7 (9.0)
Gender, n (%)
Male 1965 (74.2) 757 (74.2)
Female 683 (25.8) 263 (25.8)
Race, n (%)
White 1497 (56.5) 613 (60.1)
Black 149 (5.6) 75 (7.4)
Asian 901 (34.0) 297 (29.1)
Other 101 (3.8) 35 (3.4)
Ethnicity, n (%)
Hispanic or Latino 613 (23.1) 227 (22.3)
Other 2035 (76.9) 793 (77.7)
Weight, kg 84.6 (19.3) 86.9 (19.8)
Known duration of diabetes, years 16.7 (9.1) 15.8 (8.5)
Systolic blood pressure, mm Hg 136.3 (15.0) 135.9 (15.7)
Diastolic blood pressure, mm Hg 74.9 (10.0) 74.9 (9.8)
Serum albumin, g/L 39.3 (3.5) 38.6 (3.8)
Serum creatinine, μmol/L 147.4 (42.0) 155.6 (45.6)
eGFR, mL/min/1.73 m2 43.8 (13.7) 41.8 (13.8)
Haemoglobin, g/L 129.3 (16.9) 129.0 (17.7)
HbA1c, % 7.8 (1.5) 7.8 (1.6)
Brain natriuretic peptide median (Q1-Q3),
(pg/mL)
49.0 [26.0-88.0] 46.0 [26.0-84.0]
Total cholesterol, mmol/L 4.6 (1.2) 4.6 (1.2)
LDL cholesterol, mmol/L 2.7 (1.0) 2.8 (1.0)
HDL cholesterol, mmol/L 1.2 (0.4) 1.1 (0.3)
Triglycerides, mmol/L 2.5 (2.2) 2.6 (2.0)
Serum potassium, mmol/L 4.5 (0.6) 4.5 (0.5)
UACR, median (Q1-Q3), mg/g creatinine 802 [450-1466] 920 [474-1858]
Antihypertensives, n (%)
RAS inhibitors, n (%) 2594 (98.0) 998 (97.8)
Beta blockers, n (%) 1103 (41.7) 396 (38.8)
Calcium channel blockers, n (%) 1526 (57.6) 581 (57.0)
Diuretics, n (%) 2186 (82.6) 828 (81.2)
Loop diuretics 1338 (50.5) 522 (51.2)
Thiazides 795 (30.0) 275 (27.0)
Othera 289 (10.9) 115 (11.3)
Glucose-lowering therapies, n (%)
Insulin glargine 1654 (62.5) 655 (64.2)
Metformin 1009 (38.1) 344 (33.7)
Sulphonylurea 751 (28.4) 280 (27.5)
Statins, n (%) 2075 (78.4) 809 (79.3)
History of coronary artery disease, n (%) 287 (10.8) 111 (10.9)
History of myocardial infarction, n (%) 160 (6.0) 74 (7.3)
History of diabetic retinopathy, n (%) 905 (34.2) 290 (28.4)
a Other includes chlortalidone, indapamide, mefruside, metolazone, tripamide and xipamide.
Although numerical differences were small in all parameters, differences between responders and non-responders reached statistical significance (P ≤ .05)
for the following characteristics: age, race, bodyweight, known duration of diabetes, serum albumin, serum creatinine, eGFR, metformin use, and history of
diabetic retinopathy.
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The similarity in baseline characteristics suggests that none of the
clinically used biochemical or physical parameters can be used to differ-
entiate between atrasentan responder and non-responder patients, and
may also be unable to detect the risks of progressing to end-stage renal
or cardiovascular disease upon entry to the SONAR trial. Further exami-
nation of the stored plasma and urine samples is required to determine
if novel biomarkers measured before atrasentan exposure can help in
differentiating atrasentan responders from non-responders.
Responses in most cardio-renal risk markers were remarkably sim-
ilar in the responder and non-responder populations, except for eGFR
and systolic blood pressure. It is, however, very unlikely that the small
difference in blood pressure changes between responders and non-
responders explains the large separation in UACR responses. The
reduction in eGFR in the responder population probably reflects a
reduction in intraglomerular pressure as ERAs acutely modify renal
vascular tone, and may in part explain the reduction in UACR.8,9
Intriguingly, changes in bodyweight, BNP and haemoglobin, as proxies
of sodium and fluid retention, were similar for atrasentan responders
and non-responders. These data support previous findings indicating
that the sodium and fluid retention response to atrasentan is not
coupled to the albuminuria-lowering effect.10 The uncoupling of the
albuminuria response from responses in other cardio-renal risk
markers is not unique to atrasentan. Previous studies with SGLT2
inhibitors and glucagon-like peptide 1 receptor antagonists reported
that the albuminuria-lowering effect of these agents occurs regardless
of responses in other cardio-renal risk markers.11–13 Because only
modest differences in blood pressure and eGFR were noted, and all
other measured biochemical and physical cardio-renal risk markers
were similar for atrasentan responders and non-responders, it is possi-
ble to speculate that any potential renoprotective effect of atrasentan
is probably mediated by a reduction in UACR, although other unmea-
sured effects may be involved as well.
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FIGURE 1 Changes in renal risk markers
after 6 weeks of treatment with atrasentan.
Data are presented as mean (95% CI).
Numbers below each bar indicate mean
(95% CI) change. Although numerical
differences were small, due to the large
samples, size differences between
responders and non-responders reached
statistical significance (P ≤ .05) in all
parameters except BNP, potassium, and
Hba1c
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During the recruitment for the SONAR trial, SGLT2 inhibitors
were already being used by a few patients. Based on the positive
results of recent and ongoing trials with these agents in patients with
T2D, SGLT2 inhibitors may become part of the standard therapeutic
management to delay progression of renal disease in patients with
T2D. This study's discovery that the albuminuria-lowering effects of
atrasentan are similar regardless of concomitant SGLT2 use suggests
that ERAs could complement SGLT2 inhibitors in delaying progressive
renal function decline. A drug–drug interaction study is required to
test this hypothesis.
The large UACR reduction during the enrichment phase had
important implications for the predefined design of the SONAR trial.
Throughout the ongoing follow-up period of the SONAR trial, the
steering committee and AbbVie regularly reviewed the event rate for
the primary renal outcomes, and they observed a much lower event
rate than had originally been expected. If this was not due to a large
treatment effect, then this lower than expected event rate could
reduce the predefined power of the trial. Although it was possible that
the carefully selected enrolled population had a genuinely very low
renal risk, this explanation appeared improbable, considering that the
baseline and response characteristics of the responder population
were similar to those of the non-responder population. On the other
hand, the large UACR reduction observed in the responder population
supports the possibility of a large renoprotective effect.
The lower than expected event rate meant that, in order to collect
the planned 425 primary endpoints, a very long follow-up period
would be needed, and that was not feasible. Consequently, the spon-
sor made a decision not to continue with the ongoing follow-ups, and
the clinical trial sites were notified accordingly in late 2017. At the
point when the trial was stopped, more than 121 projected renal
events were set to be accumulated, resulting in more than 90% power
to detect a hazard ratio of 0.55, and more than 80% power to detect a
hazard ratio of 0.60. While these effect sizes are larger than originally
planned (the trial had been designed to detect a hazard ratio of 0.73),
both the CANVAS and EMPAREG trials observed risk reduction of a
similar magnitude, despite reductions in albuminuria that were of a
lesser magnitude than those observed among the responder popula-
tion in SONAR.14,15 The results of the SONAR trial are expected to be
available in 2018.
In conclusion, the SONAR trial enrolled 3668 patients with T2D
mellitus and kidney disease who are at high risk of progressive renal
dysfunction and cardiovascular events. The enrichment period suc-
cessfully identified an atrasentan UACR responder population which
could not be separated from non-responders by a standard panel of
biochemical or physical characteristics. This selection of patients
showing a profound UACR reduction without clinical signs of sodium
and fluid retention supports the possibility of a large atrasentan effect
on renal outcomes of clinical and regulatory importance. The final
results of the SONAR trial will deliver definitive evidence of the long-
term efficacy and safety of atrasentan in this enriched population.
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